NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

 Proposed Single Technology Appraisal (STA)

**Benralizumab for treating inadequately controlled asthma ID1129**

Provisional matrix of consultees and commentators

| **Consultees** | **Commentators (no right to submit or appeal)** |
| --- | --- |
| CompanyAstraZeneca (benralizumab) Patient/carer groups* Action Against Allergy
* Action for sick children
* Allergy UK
* Asthma Trust for Asthmatic Children
* Asthma UK
* British Lung Foundation
* Muslim Council of Britain
* NARA – The Breathing Charity
* National Children’s Bureau
* South Asian Health Foundation
* Specialised Healthcare Alliance

Professional groups* Association of Respiratory Nurse Specialists
* British Geriatrics Society
* British Paediatric Respiratory Society
* British Society for Allergy & Clinical Immunology
* British Thoracic Society
* Primary Care Respiratory Society UK
* Royal College of General Practitioners
* Royal College of Nursing
* Royal College of Paediatrics & Child Health
* Royal College of Pathologists
* Royal College of Physicians
* Royal Pharmaceutical Society
* Royal Society of Medicine
* UK Clinical Pharmacy Association

Others* Department of Health
* NHS England
* NHS Heywood, Middleton and Rochdale CCG
* NHS Hounslow CCG
* Welsh Government
 | General* Allied Health Professionals Federation
* Asthma Relief Charity
* Board of Community Health Councils in Wales
* British National Formulary
* Care Quality Commission
* Department of Health, Social Services and Public Safety for Northern Ireland
* Healthcare Improvement Scotland
* Medicines and Healthcare Products Regulatory Agency
* National Association of Primary Care
* National Pharmacy Association
* NHS Alliance
* NHS Commercial Medicines Unit
* NHS Confederation
* Scottish Medicines Consortium

Possible comparator companies* GlaxoSmithKline (mepolizumab)
* Teva Pharmaceuticals (reslizumab)

Relevant research groups* Asthma, Allergy and Inflammation Research Trust
* British Association for Lung Research
* Cochrane Airways Group
* MRC Clinical Trials Unit
* National Institute for Health Research
* National Society for Research into Allergy

Associated Public Health groups* Public Health England
* Public Health Wales
 |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

*PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS*

**Definitions:**

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement[[1]](#footnote-1), respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-company commentators are invited to nominate clinical specialists or patient experts.

1. Non-company consultees are invited to submit statements relevant to the group they are representing. [↑](#footnote-ref-1)